{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:45:20Z","timestamp":1792622720342,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Ovarian cancer (OC), a kind of gynecological cancer, is characterized by high mortality rate, with microRNAs (miRNAs) playing essential roles in it. However, the clinical significance of miRNAs and their molecular mechanisms in OC are mostly unknown.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>miR-149-3p expression was predicted through Gene Expression Omnibus (GEO) data in OC and confirmed by q-PCR in various OC cells and tissues from patients with different clinical characteristics. Moreover, its roles in terms of proliferation, migration and invasion were measured by CCK-8, colony formation, wound healing and transwell assays in OC cells including cisplatin-resistant and cisplatin-sensitive cells. And its effect on epithelial-mesenchymal transition was also assessed through detecting related protein expression. Additionally, its potential targets were verified by dual luciferase assay and Ago-RIP assay. Finally, its oncogenic functions were explored in vivo.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In data from GSE79943, GSE131790, and TCGA, miR-149-3p was found to be highly expressed in OC tissues and associated with poor survival. In metastasis and chemoresistant tissues and cisplatin-resistant OC cells, its high expression was confirmed. In terms of tumorigenic effects, miR-149-3p knockdown in cisplatin-resistant OC cells inhibited its cisplatin resistance and other malignant phenotypes, while miR-149-3p overexpression in cisplatin-resistant OC cells led to contrary results. Mechanistically, miR-149-3p targeted 3\u2019UTR of CDKN1A and TIMP2 to function as an oncogenic miRNA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In brief<jats:bold>,<\/jats:bold> miR-149-3p promoted cisplatin resistance and EMT in OC by downregulating CDKN1A and TIMP2, which might provide a potential therapeutic target for OC treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13048-021-00919-5","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T16:03:41Z","timestamp":1637337821000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A"],"prefix":"10.1186","volume":"14","author":[{"given":"Jin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,19]]},"reference":[{"key":"919_CR1","unstructured":"Cancer I A f R o. Estimated number of incident cases from 2018 to 2040 2020. Available from: https:\/\/gco.iarc.fr\/tomorrow\/graphic-isotype."},{"key":"919_CR2","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1097\/AOG.0000000000004173","volume":"137","author":"KC Kurnit","year":"2021","unstructured":"Kurnit KC, Fleming GF, Lengyel E. Updates and new options in advanced epithelial ovarian Cancer treatment. Obstet Gynecol. 2021;137:108\u201321.","journal-title":"Obstet Gynecol"},{"key":"919_CR3","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/humupd\/dmz027","volume":"25","author":"N Spears","year":"2019","unstructured":"Spears N, Lopes F, Stefansdottir A, Rossi V, De Felici M, Anderson RA, et al. Ovarian damage from chemotherapy and current approaches to its protection. Hum Reprod Update. 2019;25:673\u201393.","journal-title":"Hum Reprod Update"},{"key":"919_CR4","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.1002\/jcp.27486","volume":"234","author":"K Saliminejad","year":"2019","unstructured":"Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, Ghaffari SH. An overview of microRNAs: biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019;234:5451\u201365.","journal-title":"J Cell Physiol"},{"key":"919_CR5","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.jaci.2017.08.034","volume":"141","author":"TX Lu","year":"2018","unstructured":"Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2018;141:1202\u20137.","journal-title":"J Allergy Clin Immunol"},{"key":"919_CR6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00018-018-2940-7","volume":"76","author":"M Pu","year":"2019","unstructured":"Pu M, Chen J, Tao Z, Miao L, Qi X, Wang Y, et al. Regulatory network of miRNA on its target: coordination between transcriptional and post-transcriptional regulation of gene expression. Cell Mol Life Sci. 2019;76:441\u201351.","journal-title":"Cell Mol Life Sci"},{"key":"919_CR7","doi-asserted-by":"crossref","unstructured":"Sinigaglia A, Peta E, Riccetti S, Venkateswaran S, Manganelli R, Barzon L. Tuberculosis-associated MicroRNAs: from pathogenesis to disease biomarkers. Cells. 2020;9:2160.","DOI":"10.3390\/cells9102160"},{"key":"919_CR8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.7150\/thno.29055","volume":"9","author":"L Ren","year":"2019","unstructured":"Ren L, Chen H, Song J, Chen X, Lin C, Zhang X, et al. MiR-454-3p-mediated Wnt\/\u03b2-catenin signaling antagonists suppression promotes breast Cancer metastasis. Theranostics. 2019;9:449\u201365.","journal-title":"Theranostics."},{"key":"919_CR9","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ymthe.2019.09.008","volume":"28","author":"Y Xu","year":"2020","unstructured":"Xu Y, Xu Y, Zhu Y, Sun H, Juguilon C, Li F, et al. Macrophage miR-34a is a key regulator of cholesterol efflux and atherosclerosis. Mol Ther. 2020;28:202\u201316.","journal-title":"Mol Ther"},{"key":"919_CR10","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ymthe.2019.11.016","volume":"28","author":"X Chen","year":"2020","unstructured":"Chen X, Xu M, Xu X, Zeng K, Liu X, Sun L, et al. METTL14 suppresses CRC progression via regulating N6-Methyladenosine-dependent primary miR-375 processing. Mol Ther. 2020;28:599\u2013612.","journal-title":"Mol Ther"},{"key":"919_CR11","doi-asserted-by":"publisher","first-page":"8206","DOI":"10.7150\/thno.37455","volume":"9","author":"L He","year":"2019","unstructured":"He L, Zhu W, Chen Q, Yuan Y, Wang Y, Wang J, et al. Ovarian cancer cell-secreted exosomal miR-205 promotes metastasis by inducing angiogenesis. Theranostics. 2019;9:8206\u201320.","journal-title":"Theranostics."},{"key":"919_CR12","doi-asserted-by":"publisher","first-page":"8771","DOI":"10.7150\/thno.46142","volume":"10","author":"HC Hong","year":"2020","unstructured":"Hong HC, Chuang CH, Huang WC, Weng SL, Chen CH, Chang KH, et al. A panel of eight microRNAs is a good predictive parameter for triple-negative breast cancer relapse. Theranostics. 2020;10:8771\u201389.","journal-title":"Theranostics."},{"key":"919_CR13","doi-asserted-by":"publisher","first-page":"10765","DOI":"10.2147\/OTT.S271606","volume":"13","author":"CT Xiao","year":"2020","unstructured":"Xiao CT, Lai WJ, Zhu WA, Wang H. MicroRNA derived from circulating Exosomes as noninvasive biomarkers for diagnosing renal cell carcinoma. Onco Targets Ther. 2020;13:10765\u201374.","journal-title":"Onco Targets Ther"},{"key":"919_CR14","first-page":"4149","volume":"23","author":"HY Liu","year":"2019","unstructured":"Liu HY, Zhang YY, Zhu BL, Feng FZ, Yan H, Zhang HY, et al. miR-21 regulates the proliferation and apoptosis of ovarian cancer cells through PTEN\/PI3K\/AKT. Eur Rev Med Pharmacol Sci. 2019;23:4149\u201355.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"919_CR15","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/1878-0261.12588","volume":"14","author":"S Chava","year":"2020","unstructured":"Chava S, Reynolds CP, Pathania AS, Gorantla S, Poluektova LY, Coulter DW, et al. miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma. Mol Oncol. 2020;14:180\u201396.","journal-title":"Mol Oncol"},{"key":"919_CR16","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.lfs.2019.05.018","volume":"228","author":"I Papathanasiou","year":"2019","unstructured":"Papathanasiou I, Trachana V, Mourmoura E, Tsezou A. DNA methylation regulates miR-140-5p and miR-146a expression in osteoarthritis. Life Sci. 2019;228:274\u201384.","journal-title":"Life Sci"},{"key":"919_CR17","first-page":"1","volume":"51","author":"JS Kim","year":"2019","unstructured":"Kim JS, Kim EJ, Lee S, Tan X, Liu X, Park S, et al. MiR-34a and miR-34b\/c have distinct effects on the suppression of lung adenocarcinomas. Exp Mol Med. 2019;51:1\u201310.","journal-title":"Exp Mol Med"},{"key":"919_CR18","first-page":"2431","volume":"11","author":"Y Li","year":"2019","unstructured":"Li Y, Zhu H, Wang J, Qian X, Li N. miR-4513 promotes breast cancer progression through targeting TRIM3. Am J Transl Res. 2019;11:2431\u20138.","journal-title":"Am J Transl Res"},{"key":"919_CR19","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68:284\u201396.","journal-title":"CA Cancer J Clin"},{"key":"919_CR20","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ygyno.2020.08.028","volume":"159","author":"H Plett","year":"2020","unstructured":"Plett H, Filippova OT, Garbi A, Kommoss S, Rosendahl M, Langstraat C, et al. Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study. Gynecol Oncol. 2020;159:434\u201341.","journal-title":"Gynecol Oncol"},{"key":"919_CR21","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/s41418-018-0088-5","volume":"25","author":"A Bellazzo","year":"2018","unstructured":"Bellazzo A, Di Minin G, Valentino E, Sicari D, Torre D, Marchionni L, et al. Cell-autonomous and cell non-autonomous downregulation of tumor suppressor DAB2IP by microRNA-149-3p promotes aggressiveness of cancer cells. Cell Death Differ. 2018;25:1224\u201338.","journal-title":"Cell Death Differ"},{"key":"919_CR22","doi-asserted-by":"publisher","first-page":"190061","DOI":"10.1098\/rsob.190061","volume":"9","author":"M Zhang","year":"2019","unstructured":"Zhang M, Gao D, Shi Y, Wang Y, Joshi R, Yu Q, et al. miR-149-3p reverses CD8(+) T-cell exhaustion by reducing inhibitory receptors and promoting cytokine secretion in breast cancer cells. Open Biol. 2019;9:190061.","journal-title":"Open Biol"},{"key":"919_CR23","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1158\/1078-0432.CCR-19-0190","volume":"26","author":"H Xu","year":"2020","unstructured":"Xu H, Zhao X, Bhojwani D, Shuyu E, Goodings C, Zhang H, et al. ARID5B influences antimetabolite drug sensitivity and prognosis of acute lymphoblastic leukemia. Clin Cancer Res. 2020;26:256\u201364.","journal-title":"Clin Cancer Res"},{"key":"919_CR24","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s12935-019-1051-3","volume":"19","author":"H Guo","year":"2019","unstructured":"Guo H, Ha C, Dong H, Yang Z, Ma Y, Ding Y. Cancer-associated fibroblast-derived exosomal microRNA-98-5p promotes cisplatin resistance in ovarian cancer by targeting CDKN1A. Cancer Cell Int. 2019;19:347.","journal-title":"Cancer Cell Int"},{"key":"919_CR25","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.ymthe.2020.11.018","volume":"29","author":"X Geng","year":"2021","unstructured":"Geng X, Zhao J, Huang J, Li S, Chu W, Wang WS, et al. lnc-MAP 3K13\u20137:1 Inhibits Ovarian GC Proliferation in PCOS via DNMT1 Downregulation-Mediated CDKN1A Promoter Hypomethylation. Mol Ther. 2021;29:1279\u201393.","journal-title":"Mol Ther"},{"key":"919_CR26","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1158\/0008-5472.CAN-19-2416","volume":"80","author":"E Giurisato","year":"2020","unstructured":"Giurisato E, Lonardi S, Telfer B, Lussoso S, Risa-Ebr\u00ed B, Zhang J, et al. Extracellular-regulated protein kinase 5-mediated control of p21 expression promotes macrophage proliferation associated with tumor growth and metastasis. Cancer Res. 2020;80:3319\u201330.","journal-title":"Cancer Res"},{"key":"919_CR27","doi-asserted-by":"publisher","first-page":"5722","DOI":"10.1002\/jcp.29507","volume":"235","author":"J Wang","year":"2020","unstructured":"Wang J, Zhang Q, Wang D, Yang S, Zhou S, Xu H, et al. Microenvironment-induced TIMP2 loss by cancer-secreted exosomal miR-4443 promotes liver metastasis of breast cancer. J Cell Physiol. 2020;235:5722\u201335.","journal-title":"J Cell Physiol"},{"key":"919_CR28","doi-asserted-by":"publisher","first-page":"11963","DOI":"10.7150\/thno.50093","volume":"10","author":"Z Liu","year":"2020","unstructured":"Liu Z, Yang D, Gao J, Xiang X, Hu X, Li S, et al. Discovery and validation of miR-452 as an effective biomarker for acute kidney injury in sepsis. Theranostics. 2020;10:11963\u201375.","journal-title":"Theranostics."}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-021-00919-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-021-00919-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-021-00919-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T16:04:47Z","timestamp":1637337887000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-021-00919-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,19]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["919"],"URL":"https:\/\/doi.org\/10.1186\/s13048-021-00919-5","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,19]]},"assertion":[{"value":"31 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research program was approved by the Banan People\u2019s hospital of Chongqing ethics committee. Signed informed consent was obtained from all patients and their families.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"165"}}